Print  |  Font Size Change Font Size
Search naabt.org  

The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

Naltrexone? What is it and what does it do?


A narcotic antagonist, works by blocking opioid receptors in the brain, without activating them, therefore, blocking the effects of opioids (e.g., heroin, morphine). Naltrexone has a High affinity to the Mu receptor, yet not as high as buprenorphine. Naltrexone was first synthesized in 1965. It was approved by the FDA in 1984 for preventing relapse in opioid addicted patients. Later in 1994 the FDA approved it to treat alcoholism, it tends to reduce cravings for alcohol. Naltrexone binds to the opioid receptors stronger then other opioids (except buprenorphine) this results in near complete blocking of opioids. Naltrexone is not used extensively because the retention rate of patients is very low. Unlike buprenorphine Naltrexone does not activate the opioid receptors at all, so any lingering withdrawal, or pain from a compromised endogenous opioid system will still exist.



Back to FAQs

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release